Literature DB >> 31606525

Efficacy of semaglutide versus liraglutide in clinical practice.

E Goncalves1, D S Bell2.   

Abstract

Keywords:  Glucagon-like peptide-1; Glycaemic control; Liraglutide; Receptor agonist; Semaglutide; Type 2 diabetes

Mesh：

Substances：

Year:  2019        PMID： 31606525     DOI： 10.1016/j.diabet.2019.10.001

Source DB:  PubMed          Journal:  Diabetes Metab        ISSN： 1262-3636            Impact factor:   6.041


× No keyword cloud information.
  7 in total

1.  Evaluation of Patient-Reported Satisfaction and Clinical Efficacy of Once-Weekly Semaglutide in Patients with Type 2 Diabetes: An Ambispective Study.

Authors:  Ayman A Al Hayek; Mohamed A Al Dawish
Journal:  Adv Ther       Date:  2022-02-04       Impact factor: 3.845

2.  Two birds one stone: semaglutide is highly effective against severe psoriasis in a type 2 diabetic patient.

Authors:  Gabriele Costanzo; Salvatore Curatolo; Barbara Busà; Antonino Belfiore; Damiano Gullo
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2021-08-01

3.  Real-world use of once-weekly semaglutide in patients with type 2 diabetes: pooled analysis of data from four SURE studies by baseline characteristic subgroups.

Authors:  Jean-François Yale; Ulrik Bodholdt; Andrei-Mircea Catarig; Sergiu Catrina; Alice Clark; Neda Rajamand Ekberg; Umut Erhan; Patrick Holmes; Søren Tang Knudsen; Joanne Liutkus; Thozhukat Sathyapalan; Bernd Schultes; Gottfried Rudofsky
Journal:  BMJ Open Diabetes Res Care       Date:  2022-04

4.  Real-world evaluation of weekly subcutaneous treatment with semaglutide in a cohort of Italian diabetic patients.

Authors:  P Marzullo; T Daffara; C Mele; M Zavattaro; A Ferrero; M Caputo; F Prodam; G Aimaretti
Journal:  J Endocrinol Invest       Date:  2022-04-16       Impact factor: 5.467

5.  Use of once-weekly semaglutide in patients with type 2 diabetes in routine clinical practice: Results from the SURE Canada multicentre, prospective, observational study.

Authors:  Jean-François Yale; Andrei-Mircea Catarig; Katrine Grau; Stewart Harris; Agnieszka Klimek-Abercrombie; Rémi Rabasa-Lhoret; Laura Reardon; Vincent Woo; Joanne Liutkus
Journal:  Diabetes Obes Metab       Date:  2021-08-15       Impact factor: 6.408

6.  Semaglutide once weekly in people with type 2 diabetes: Real-world analysis of the Canadian LMC diabetes registry (SPARE study).

Authors:  Ruth E Brown; Peter G Bech; Ronnie Aronson
Journal:  Diabetes Obes Metab       Date:  2020-07-13       Impact factor: 6.577

7.  Switching between GLP-1 receptor agonists in clinical practice: Expert consensus and practical guidance.

Authors:  Akshay B Jain; Amar Ali; Juan J Gorgojo Martínez; Irene Hramiak; Ketan Kavia; Sten Madsbad; Louis Potier; Ben D Prohaska; Jodi L Strong; Tina Vilsbøll
Journal:  Int J Clin Pract       Date:  2020-11-03       Impact factor: 2.503
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.